Family-controlled Indian conglomerate Piramal Group plans to make a big investment internationally as it seeks growth outside of its home market.
A spokesman for the company, which operates in a number of areas including pharmaceuticals, real estate and healthcare, told CampdenFB that the Piramal family will invest around $1.5 billion in mostly biotech companies in the US and Europe.
“The investment is part of our ongoing strategic diversification efforts,” he said.
